Yondelis filed for US approval for relapsed ovarian cancer
This article was originally published in Scrip
Executive Summary
Ortho Biotech (Johnson & Johnson) has filed an NDA with the US FDAfor the chemotherapy drug Yondelis (trabectedin), licensed from PharmaMar, for the treatment of relapsed ovarian cancer.